Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
NCT ID NCT06647654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks how well the ABRYSVO® vaccine protects infants from severe RSV when given to pregnant women. Researchers will look at hospital records from Argentina and Uruguay over several RSV seasons. The goal is to see if the vaccine reduces hospitalizations and severe illness in babies up to 6 months old.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Buenos Aires, Argentina
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine given during pregnancy shield infants from a deadly virus?
- Simple blood test could slash antibiotic overuse for coughs and colds
- Blood thinners may be unnecessary for minor lung clots, new trial suggests
- New bird flu booster shot shows promise in early trial
- New ibuzatrelvir tablet put to the test in healthy volunteers
- Moderna's mRNA vaccine cocktail passes early safety check